Combined Synopisis-Solicitation 75N94025Q00181.pdf

COMBINED SYNOPSIS / SOLICITATION

WORKFORM

(1) Action Code: Combined Synopsis/Solicitation

(2) Date: 08/12/2025

(3) Year: 2025

(4) Contracting Office Zip Code: 20892

(5) Product Classification Code: 6550 - In Vitro Diagnostic Substances, Reagents, Test Kits and Sets

(6) Contracting Office Address:

Acquisitions Services Branch 6710-B Rockledge Drive Bethesda, MD 20817

(7) Subject/Title: 10X Genomics Reagent Kits for NIDDK

(8) Solicitation Number: 75N94025Q00181

(9) Closing Response Date: 08/19/2025 1700 ED

(10) Contact Point: Jacob Balenson, Contracting Officer

(11) Contract Award Number: TBD

(12) Contract Award Dollar Amount: TBD

(13) Contract Line Item Number(s): TBD

(14) Contract Award Date: TBD

(15) Contractor Name: TBD

(16) Background: The NIDDK explores how cells maintain homeostasis in various tissues of the digestive, kidney, and related systems and how that balance breaks down to drive disease. To pinpoint the molecular switches that tip systems of the body from healthy to harmful, our institute profiles tissue resident and homing cells (such as inflammatory immune cells) directly within affected tissue.

Standard bulk and microdissection spatial methods average signals across millions of cells and mask the critical differences that spark disease. The 10x Genomics single-cell and spatial kits solve this problem. Single-cell RNA-seq tells NIDDK which genes are turned on, while spatial workflows let us pinpoint where those cells and molecules are pinpointed within tissue. Merging these readouts gives us a highresolution atlas of gene expression across tissues and disease states with healthy controls.

These data are essential for the NIDDK mission: they reveal the exact pathways that malfunction, identify new drug targets, and guide the development of precision therapies to halt or diseases of major body system organs.

(17) Description of the Requirement: The purpose of this procurement is to acquire a bundled set of 10x Genomics consumables and an instrument upgrade needed for single-cell and spatial transcriptomics projects, as follows: Single-cell RNA-seq reagents (Chromium Next GEM v3.1 chemistry), Single-cell RNA + TCR-seq kits for comprehensive immune-repertoire profiling, Spatial transcriptomics reagents for the Xenium In Situ, Visium HD, and Visium HD-3′ workflows, and an instrument trade-up/upgrade of our existing Chromium Controller to a CytAssist. Together, these items will allow high-resolution mapping of cellular states and spatial gene expression across multiple NIDDK projects. See Attachment 1 -Statement of Need, Section 4.0 REQUIREMENTS for brand-name items list.

a. This is a combined synopsis/solicitation for commercial items with a brand-name description prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued.

b. The solicitation number is 75N94025Q00181 and the solicitation is issued as a request for quote

(RFQ).

c. The provisions and clauses incorporated in this solicitation document are those in effect through Federal Acquisition Circular 2025-05 effective 08/07/2025. The acquisition is being conducted in accordance with the procedures of FAR Part 12, and FAR Part 13. In accordance with FAR 5.102(a)(6), the Contracting Officer has included with the solicitation the justification/ documentation required FAR 13.106-1(b).

d. The associated NAICS code is 325413 - In Vitro Diagnostic Substance Manufacturing and the small business size standard in number of employees is 1,250. This is a total small business set-aside.

e. Period of Performance: The Government anticipates delivery by 60 Days After Receipt of Order (ARO). Delivery Location: National Institutes of Health, NIDDK Bldg 10 / Room 10S227, 9000 Rockville Pike, Maryland 20892

f. The award will be made based on best value. Quotes will be evaluated based on the following factors: Cost/Price, Past Performance, Delivery Terms, and Technical Capability to meet the requirements outlined in the Statement of Need. See Attachment 2 - Evaluation Criteria.

g. Responses are to include a completed copy of FAR 52.212-3 Offeror Representations and Certifications—Commercial Products and Commercial Services [(DEVIATION FEB 2025)]. Note:

The Offeror shall complete only paragraph (b) of this provision if the Offeror has completed the annual representations and certification electronically in the System for Award Management (SAM) accessed through https://www.sam.gov. If the Offeror has not completed the annual representations and certifications electronically, the Offeror shall complete only paragraphs (c) through (v) of this provision.

h. FAR 52.212-4, Contract Terms and Conditions – Commercial Items, applies to this acquisition.

Note: NIH Invoice and Payment Provisions are added as an addendum to this clause. See Attachment 3 - NIH Invoice and Payment Provisions.

i. FAR 52.212-5 Contract Terms and Conditions Required To Implement Statutes or Executive Orders—Commercial Products and Commercial Services [(DEVIATION FEB 2025)], applies to this acquisition and is attached in full text. See Attachment 4 - FAR 52.212-5 (JAN 2025)

[(DEVIATION FEB 2025)] 75N94025Q00181.

j. Additional Clauses:

FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation FAR 52.204-7 System for Award Management.

FAR 52.204-13 System for Award Management Maintenance HHSAR 352.232-71 Electronic submission of payment requests

k. Responses to this notice shall contain sufficient information to establish the interested parties capabilities for fulfilling the requirement. All respondents must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses to this notice shall be submitted electronically by 5:00 PM ED, on 08/19/2025 to jacob.balenson@nih.gov and shall include solicitation number 75N94024Q00091 in the subject line.

l. Primary Point of Contact: Jacob Balenson, Contracting Officer, Email:

jacob.balenson@nih.gov